Prevention of bleeding in hemophilia patients with high-titer inhibitors
Data
2015-06-01
Autores
Antunes, Sandra V. 
Tipo
Artigo
Título da Revista
ISSN da Revista
Título de Volume
Resumo
Inhibitor development is the most serious adverse event linked to the treatment of hemophilia, as it renders standard hemostatic therapy ineffective. Consequently, inhibitor patients are at increased risk for difficult-to-control bleeding and complications, particularly arthropathy and physical disability. Three randomized clinical trials in patients with inhibitors have demonstrated that compared with on-demand bypassing therapy, prophylaxis with a bypassing agent reduces joint and other types of bleeding and improves health-related quality of life. in hemophilia patients without inhibitors, the initiation of prophylaxis with factor (F) VIII or IX prior to the onset of recurrent hemarthroses can prevent the development of joint disease. Whether this is also true for bypassing agent prophylaxis remains to be determined.
Descrição
Citação
Expert Review of Hematology. London: Expert Reviews, v. 8, n. 3, p. 375-382, 2015.